## Katsuaki Ieguchi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6467839/publications.pdf

Version: 2024-02-01

		687363	839539	
18	468	13	18	
papers	citations	h-index	g-index	
19	19	19	681	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Eph/Ephrin Signaling in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2021, 1270, 45-56.	1.6	4
2	Analysis of ADAM12-Mediated Ephrin-A1 Cleavage and Its Biological Functions. International Journal of Molecular Sciences, 2021, 22, 2480.	4.1	11
3	Roles of EphA1/A2 and ephrinâ€A1 in cancer. Cancer Science, 2019, 110, 841-848.	3.9	49
4	C1D is not directly involved in the repair of UV-damaged DNA but protects cells from oxidative stress by regulating gene expressions in human cell lines. Journal of Biochemistry, 2018, 164, 415-426.	1.7	3
5	Paradoxical counteraction by imatinib against cell death in myeloid progenitor 32D cells expressing p210BCR-ABL. Oncotarget, 2018, 9, 31682-31696.	1.8	4
6	Savior or not: ADAM17 inhibitors overcome radiotherapy-resistance in non-small cell lung cancer. Journal of Thoracic Disease, 2016, 8, E813-E813.	1.4	19
7	Intracellular LINGO-1 negatively regulates Trk neurotrophin receptor signaling. Molecular and Cellular Neurosciences, 2016, 70, 1-10.	2.2	16
8	Human Serum Amyloid A3 (SAA3) Protein, Expressed as a Fusion Protein with SAA2, Binds the Oxidized Low Density Lipoprotein Receptor. PLoS ONE, 2015, 10, e0118835.	2.5	21
9	LINGO-1 Protein Interacts with the p75 Neurotrophin Receptor in Intracellular Membrane Compartments. Journal of Biological Chemistry, 2015, 290, 9511-9520.	3.4	17
10	Eph as a Target in Inflammation. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2015, 15, 119-128.	1.2	18
11	ZFC3H1, a Zinc Finger Protein, Modulates IL-8 Transcription by Binding with Celastramycin A, a Potential Immune Suppressor. PLoS ONE, 2014, 9, e108957.	2.5	12
12	Ephrin-A1 expression induced by S100A8 is mediated by the toll-like receptor 4. Biochemical and Biophysical Research Communications, 2013, 440, 623-629.	2.1	21
13	An Integrin Binding-defective Mutant of Insulin-like Growth Factor-1 (R36E/R37E IGF1) Acts as a Dominant-negative Antagonist of the IGF1 Receptor (IGF1R) and Suppresses Tumorigenesis but Still Binds to IGF1R. Journal of Biological Chemistry, 2013, 288, 19593-19603.	3.4	35
14	Cross-talk between Integrin $\hat{1}\pm 6\hat{1}^24$ and Insulin-like Growth Factor-1 Receptor (IGF1R) through Direct $\hat{1}\pm 6\hat{1}^24$ Binding to IGF1 and Subsequent $\hat{1}\pm 6\hat{1}^24$ -IGF1-IGF1R Ternary Complex Formation in Anchorage-independent Conditions. Journal of Biological Chemistry, 2012, 287, 12491-12500.	3.4	44
15	Direct Binding of the EGF-like Domain of Neuregulin-1 to Integrins ( $\hat{l}\pm\hat{v}^2$ 3 and $\hat{l}\pm\hat{l}^2$ 4) Is Involved in Neuregulin-1/ErbB Signaling. Journal of Biological Chemistry, 2010, 285, 31388-31398.	3.4	71
16	A Novel Fibroblast Growth Factor-1 (FGF1) Mutant that Acts as an FGF Antagonist. PLoS ONE, 2010, 5, e10273.	2.5	21
17	The Direct Binding of Insulin-like Growth Factor-1 (IGF-1) to Integrin $\hat{l}\pm v\hat{l}^2$ 3 Is Involved in IGF-1 Signaling. Journal of Biological Chemistry, 2009, 284, 24106-24114.	3.4	79
18	Role of the Guanine Nucleotide Exchange Factor Ost in Negative Regulation of Receptor Endocytosis by the Small GTPase Rac1. Journal of Biological Chemistry, 2007, 282, 23296-23305.	3.4	23